医薬品製造の市場規模、シェア、成長分析、製剤タイプ別、投与経路別、処方タイプ別、医薬品開発別、流通チャネル別、地域別-産業予測、2025年～2032年

医薬品製造市場規模は2023年に5,720億9,000万米ドルとなり、2024年の6,630億5,000万米ドルから2032年には2兆1,588億2,000万米ドルに成長し、予測期間（2025～2032年）のCAGRは15.9%で成長する見通しです。

世界の医薬品製造市場は、重要な医療ニーズや研究、開発、薬剤生産の増加により、依然として堅調に推移しています。主な成長要因としては、人口の増加、慢性疾患の罹患率の上昇、医療技術の著しい進歩などが挙げられます。革新的な医薬品、個別化治療、生物製剤の追求は、市場のダイナミクスをさらに高めています。さらに、ヘルスケア・インフラの拡大、医療アクセスの改善を目指した政府の取り組み、製造施設に対する投資の増加が市場の成長を後押ししています。しかしながらこの分野は厳しい規制の枠組み、価格圧力、知的財産権の問題など、全体的な進展を阻害しかねない課題に直面しています。この複雑な状況は、製薬業界の利害関係者に機会と課題の両方をもたらしています。

目次

イントロダクション

• 調査の目的
• 調査範囲
• 定義

調査手法

• 情報調達
• 二次データと一次データの方法
• 市場規模予測
• 市場の前提条件と制限

エグゼクティブサマリー

• 世界市場の見通し
• 供給と需要の動向分析
• セグメント別機会分析

市場力学と見通し

• 市場概要
• 市場規模
• 市場力学
  • 促進要因と機会
  • 抑制要因と課題
• ポーターの分析

主な市場の考察

• 重要成功要因
• 競合の程度
• 主な投資機会
• 市場エコシステム
• 市場の魅力指数（2024年）
• PESTEL分析
• マクロ経済指標
• バリューチェーン分析
• 価格分析
• 規制情勢
• 特許分析
• ケーススタディ
• 顧客と購買基準の分析
• 貿易分析

医薬品製造の市場規模：製剤タイプ別& CAGR（2025-2032）

• 市場概要
• 経口製剤
  • 錠剤
  • カプセル
  • 粉末
• 注射剤
  • 液体注射
  • 凍結乾燥注射剤
• 局所用製剤
  • クリーム
  • 軟膏
  • ジェル
• 吸入製剤
  • ドライパウダー吸入器（DPI）
  • 定量噴霧式吸入器（MDI）
• その他
  • 坐薬
  • パッチ

医薬品製造の市場規模：投与経路別& CAGR（2025-2032）

• 市場概要
• 経口
• 非経口
• 局所
• 吸入
• 経皮
• その他

医薬品製造の市場規模：処方タイプ別& CAGR（2025-2032）

• 市場概要
• 処方薬
• 市販薬（OTC）

医薬品製造の市場規模：医薬品開発別& CAGR（2025-2032）

• 市場概要
• 前臨床開発
• 臨床試験
  • フェーズI
  • フェーズII
  • フェーズIII
• 規制当局の承認
• 商業生産

医薬品製造の市場規模：流通チャネル別& CAGR（2025-2032）

• 市場概要
• 病院薬局
• 小売薬局
• オンライン薬局
• その他

医薬品製造の市場規模：地域別& CAGR（2025-2032）

• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • スペイン
  • フランス
  • 英国
  • イタリア
  • その他欧州地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• ラテンアメリカ
  • ブラジル
  • その他ラテンアメリカ地域
• 中東・アフリカ
  • GCC諸国
  • 南アフリカ
  • その他中東・アフリカ

競合情報

• 上位5社の比較
• 主要企業の市場ポジショニング（2024年）
• 主な市場企業が採用した戦略
• 市場の最近の動向
• 企業の市場シェア分析（2024年）
• 主要企業の企業プロファイル
  • 会社概要
  • 製品ポートフォリオ分析
  • セグメント別シェア分析
  • 収益の前年比比較（2022-2024）

主要企業プロファイル

• Pfizer Inc.（USA）
• Novartis AG（Switzerland）
• Roche Holding AG（Switzerland）
• Sanofi S.A.（France）
• Merck & Co., Inc.（USA）
• GlaxoSmithKline plc（UK）
• Johnson & Johnson（USA）
• AstraZeneca plc（UK）
• Eli Lilly and Company（USA）
• AbbVie Inc.（USA）
• Bristol-Myers Squibb Company（USA）
• Bayer AG（Germany）
• Amgen Inc.（USA）
• Gilead Sciences, Inc.（USA）
• Takeda Pharmaceutical Company Limited（Japan）
• Boehringer Ingelheim GmbH（Germany）
• Teva Pharmaceutical Industries Ltd.（Israel）
• Novo Nordisk A/S（Denmark）
• Astellas Pharma Inc.（Japan）
• CSL Limited（Australia）

結論と推奨事項

Pharmaceutical Manufacturing Market size was valued at USD 572.09 Billion in 2023 and is poised to grow from USD 663.05 Billion in 2024 to USD 2158.82 Billion by 2032, growing at a CAGR of 15.9% during the forecast period (2025-2032).

The global pharmaceutical manufacturing market remains robust, driven by essential healthcare demands and a surge in research, development, and drug production. Key growth factors include an increasing population, a rising incidence of chronic diseases, and significant advancements in medical technology. The pursuit of innovative drugs, personalized treatments, and biologics is further enhancing market dynamics. Additionally, the expansion of healthcare infrastructure, government initiatives aimed at improving healthcare access, and rising investments in manufacturing facilities are fueling market growth. Nevertheless, the sector faces challenges such as stringent regulatory frameworks, pricing pressures, and intellectual property rights issues that could hinder overall progress. This complex landscape presents both opportunities and hurdles for stakeholders in the pharmaceutical industry.

Top-down and bottom-up approaches were used to estimate and validate the size of the Pharmaceutical Manufacturing market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Pharmaceutical Manufacturing Market Segmental Analysis

Global Pharmaceutical Manufacturing Market is segmented by formulation type, route of administration, prescription type, drug development, distribution channel and region. Based on formulation type, the market is segmented into oral formulations, injectable formulations, topical formulations, inhalation formulations and others. Based on route of administration, the market is segmented into oral, parenteral, topical, inhalation, transdermal and others. Based on prescription type, the market is segmented into prescription drugs and over-the-counter (OTC) drugs. Based on drug development, the market is segmented into preclinical development, clinical trials, regulatory approval and commercial manufacturing. Based on distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, online pharmacies and others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Pharmaceutical Manufacturing Market

A key driver of the global pharmaceutical manufacturing market is the escalating demand for healthcare products and medications across the globe. The expanding global population, combined with a rise in chronic diseases and infectious conditions, has sparked a significant increase in the need for pharmaceuticals. Furthermore, advancements in medical technology and a growing aging demographic further elevate the demand for new and innovative treatments. In response to this escalating market need, pharmaceutical manufacturers are compelled to enhance their production capacities, invest in research and development, and implement cutting-edge manufacturing technologies, ultimately fostering robust market growth.

Restraints in the Pharmaceutical Manufacturing Market

A significant challenge facing the pharmaceutical manufacturing market is the stringent regulatory framework enforced by governments and regulatory agencies. These bodies mandate rigorous standards to ensure the safety, efficacy, and quality of pharmaceutical products, demanding substantial investments in infrastructure, quality assurance processes, and meticulous documentation. Failure to comply with these regulations can lead to severe penalties and tarnish a company's reputation. Additionally, the intricate and lengthy approval process for new drugs can slow down product launches, ultimately delaying access to vital medications for patients. These regulatory hurdles create barriers for new entrants and elevate the overall costs and timelines associated with pharmaceutical manufacturing.

Market Trends of the Pharmaceutical Manufacturing Market

The global pharmaceutical manufacturing market is experiencing a significant trend towards personalized medicine and targeted therapies, fueled by technological advancements in genomics and a demand for individualized treatments. This shift has prompted manufacturers to adapt by embracing smaller batch production and flexible manufacturing processes. Concurrently, the focus on biologics and biosimilars is intensifying due to the growing prevalence of chronic diseases and the pursuit of innovative therapeutic solutions. Sustainability also plays a crucial role, as pharmaceutical companies increasingly prioritize eco-friendly practices, waste reduction, and energy efficiency to comply with stringent environmental regulations and align with evolving consumer expectations.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Landscape
• Patent Analysis
• Case Studies
• Customer & Buying Criteria Analysis
• Trade Analysis

Global Pharmaceutical Manufacturing Market Size by Formulation Type & CAGR (2025-2032)

• Market Overview
• Oral Formulations
  • Tablets
  • Capsules
  • Powders
• Injectable Formulations
  • Liquid Injections
  • Lyophilized Injections
• Topical Formulations
  • Creams
  • Ointments
  • Gels
• Inhalation Formulations
  • Dry Powder Inhalers (DPIs)
  • Metered Dose Inhalers (MDIs)
• Others
  • Suppositories
  • Patches

Global Pharmaceutical Manufacturing Market Size by Route of Administration & CAGR (2025-2032)

• Market Overview
• Oral
• Parenteral
• Topical
• Inhalation
• Transdermal
• Others

Global Pharmaceutical Manufacturing Market Size by Prescription Type & CAGR (2025-2032)

• Market Overview
• Prescription Drugs
• Over-The-Counter (OTC) Drugs

Global Pharmaceutical Manufacturing Market Size by Drug Development & CAGR (2025-2032)

• Market Overview
• Preclinical Development
• Clinical Trials
  • Phase I
  • Phase II
  • Phase III
• Regulatory Approval
• Commercial Manufacturing

Global Pharmaceutical Manufacturing Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Others

Global Pharmaceutical Manufacturing Market Size & CAGR (2025-2032)

• North America (Formulation Type, Route of Administration, Prescription Type, Drug Development, Distribution Channel)
  • US
  • Canada
• Europe (Formulation Type, Route of Administration, Prescription Type, Drug Development, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Formulation Type, Route of Administration, Prescription Type, Drug Development, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Formulation Type, Route of Administration, Prescription Type, Drug Development, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Formulation Type, Route of Administration, Prescription Type, Drug Development, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche Holding AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim GmbH (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novo Nordisk A/S (Denmark)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Astellas Pharma Inc. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• CSL Limited (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations